Stay updated on Pembrolizumab for Cancer of Unknown Primary Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Cancer of Unknown Primary Clinical Trial page.

Latest updates to the Pembrolizumab for Cancer of Unknown Primary Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe page revision tag was updated from v3.6.4 to v3.6.5, signaling a new build of the study page. No changes to the study details or displayed information are evident.SummaryDifference0.0%

- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedThe page shows an updated revision tag to Revision: v3.6.4, reflecting an internal update to the study record. There is no indication of changes to trial content or data in this update.SummaryDifference0.0%

- Check56 days agoChange DetectedThe page shows a software revision from v3.6.2 to v3.6.3, indicating a routine site update.SummaryDifference0.0%

- Check64 days agoChange DetectedA new page revision (v3.6.2) was added, replacing the previous version (v3.6.0); this appears to be a deployment or formatting update rather than a substantive change to the study details.SummaryDifference0.0%

- Check78 days agoChange DetectedThe page now indicates recruitment has closed with 'No longer looking for participants' and adds help sections such as 'How to Read a Study Record', 'Common Questions', and 'How to Join a Study'. It also updates the revision tag to v3.6.0 and standardizes the label from 'Intervention / Treatment' to 'Intervention/Treatment'.SummaryDifference0.4%

- Check85 days agoChange DetectedA new page revision tag v3.5.5 was added, replacing the previous v3.5.4 tag. This indicates a minor update to the page record rather than a change to study content or functionality.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab for Cancer of Unknown Primary Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Cancer of Unknown Primary Clinical Trial page.